Scarica l'app Stockscreener
14.95
4.18%
0.60
Pre-mercato:
14.90
-0.05
-0.33%
Amylyx Pharmaceuticals Inc Borsa (AMLX) Ultime notizie
Amylyx (AMLX) -7.8%: Earnings Show $0 Revenue, Shelf Filing Adds Dilution Fear - Trefis
Amylyx Pharmaceuticals Inc (AMLX) Shares Up 3.52% on Apr 2 - GuruFocus
The Bull Case For Amylyx Pharmaceuticals (AMLX) Could Change Following LUCIDITY Trial Enrollment Milestone Completion - Sahm
Amylyx Pharmaceuticals, Inc. (AMLX) stock price, news, quote and history - Yahoo Finance Australia
Amylyx Pharmaceuticals (NASDAQ:AMLX) Shares Up 9%Still a Buy? - MarketBeat
Amylyx Pharmaceuticals (AMLX) Winds Up Avexitide Phase 3 Lucidity Trial Enrollment - Insider Monkey
Buyback Watch: Is Amylyx Pharmaceuticals Inc stock a smart retirement pick2026 Trade Ideas & Smart Allocation Stock Tips - baoquankhu1.vn
A Look At Amylyx Pharmaceuticals (AMLX) Valuation After LUCIDITY Phase 3 Trial Reaches Full Enrollment - simplywall.st
Is LUCIDITY Trial Completion in Post-Bariatric Hypoglycemia Altering The Investment Case For Amylyx Pharmaceuticals (AMLX)? - Yahoo Finance
AMLX Stock Price, Quote & Chart | AMYLYX PHARMACEUTICALS INC (NASDAQ:AMLX) - ChartMill
Vanguard realigns holdings; AMLX ownership reported at 0% (Vanguard) - Stock Titan
Market Recap: Is Amylyx Pharmaceuticals Inc benefiting from interest rate changesEarnings Recap Summary & Fast Gain Swing Alerts - baoquankhu1.vn
AMLX SEC FilingsAmylyx Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
HC Wainwright Reaffirms Buy Rating for Amylyx Pharmaceuticals (NASDAQ:AMLX) - MarketBeat
H.C. Wainwright reiterates Amylyx stock rating on trial progress By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Amylyx stock rating on trial progress - Investing.com
Amylyx Pharmaceuticals Advances Novel Therapies for Rare Diseases: Avexitide, AMX0035, and AMX0114 Show Promise in Clinical Trials for PBH, Wolfram Syndrome, and ALS - Minichart
Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia - BioSpace
Amylyx Highlights Pipeline Progress in Updated Corporate Presentation - TipRanks
Amylyx Pharmaceuticals completes enrollment in Phase 3 LUCIDITY trial for PBH - Traders Union
Amylyx updates presentation: LUCIDITY and LUMINA enrollment complete; LUCIDITY topline due Q3 2026 - TradingView
Amylyx (NASDAQ: AMLX) details avexitide Phase 3 timing and cash runway into 2028 - Stock Titan
Amylyx Pharmaceuticals Q4 2025 earnings preview - MSN
Amyotrophic Lateral Sclerosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals - Barchart
Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat
Amylyx Pharmaceuticals Inc (AMLX) Shares Gap Down to $13.78 on M - GuruFocus
Maven Securities LTD Makes New $951,000 Investment in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Fund Flows: Is Amylyx Pharmaceuticals Inc stock a smart retirement pickPortfolio Gains Report & Weekly Sector Rotation Insights - baoquankhu1.vn
Amylyx shares slip despite Q4 beat as investors focus on trial timeline - MSN
Amylyx Pharmaceuticals expands team to address urgent healthcare challenges - Traders Union
How Investors May Respond To Amylyx Pharmaceuticals (AMLX) Narrowed 2025 Losses And Expanded Shelf Capacity - simplywall.st
Buy Rating on Amylyx Pharmaceuticals Driven by Avexitide’s Commercial Potential and De-Risked Phase III PBH Program - TipRanks
First Light Asset Management LLC Purchases Shares of 3,355,882 Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Amylyx Pharmaceuticals, Inc. $AMLX Shares Sold by Boxer Capital Management LLC - MarketBeat
Commodore Capital Boosts Stake in Amylyx Pharmaceuticals - National Today
Commodore Capital LP Purchases Shares of 4,075,478 Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Braidwell LP Acquires Shares of 612,841 Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
437,391 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Purchased by Ally Bridge Group NY LLC - MarketBeat
Amylyx Pharmaceuticals Inc (AMLX) Shares Down 3.06% on Mar 13 - GuruFocus
Amylyx anticipates LUCIDITY trial results in Q3 2026 while advancing PBH market strategy - MSN
Amylyx Pharmaceuticals (NASDAQ:AMLX) Shares Gap DownHere's What Happened - MarketBeat
Amylyx Pharmaceuticals Highlights Avexitide LUCIDITY Phase 3 Enrollment, Q3 Data Timing at Leerink Conf. - Yahoo Finance
Amylyx Pharmaceuticals Maps High-Stakes Path to 2027 - TipRanks
[Form 4] Amylyx Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Amylyx (NASDAQ: AMLX) CFO receives new stock options and RSU grant - Stock Titan
Amylyx (NASDAQ: AMLX) Co-CEO receives new RSU and stock option grants - Stock Titan
Wall Street Zen Upgrades Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Rating - National Today
Amylyx Pharmaceuticals (AMLX) Price Target Increased by 17.82% to 15.17 - MSN
Winners Losers: How Amylyx Pharmaceuticals Inc. stock performs in weak economy2025 Market Sentiment & Real-Time Volume Surge Alerts - Naître et grandir
Amylyx Pharmaceuticals, Inc. $AMLX Position Increased by Vanguard Group Inc. - MarketBeat
Amylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):